SCHEMBL10050504

SCHEMBL10050504

COc1ccc(-c2c3nc(c(-c4ccncc4)c4ccc([nH]4)c(-c4ccc(OCCCN5C(=O)c6ccccc6C5=O)cc4)c4nc(c(-c5ccncc5)c5ccc2[nH]5)C=C4)C=C3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.52
▸ MAPT P10636 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ APEX1 P27695 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ ATM Q13315 1/20 0.44
▸ TOP1 P11387 1/20 0.43
▸ HEXA P06865 2/20 0.43
▸ HEXB P07686 2/20 0.43
▸ RECQL P46063 1/20 0.43
▸ HPGD P15428 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ BACE1 P56817 3/20 0.42
▸ TNKS2 Q9H2K2 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10050486 0.95 RAB9A (0.51) RAB9AMAPTSMN1; SMN2NPC1TOP1
SCHEMBL14528653 0.91 RAB9A (0.46) RAB9AMAPTSMN1; SMN2NPC1TOP1
SCHEMBL10074756 0.89 RAB9A (0.50) RAB9AMAPTSMN1; SMN2HSD17B10POLB
SCHEMBL10050501 0.88 RAB9A (0.44) RAB9AMAPTSMN1; SMN2NPC1TOP1
SCHEMBL10075064 0.84 RAB9A (0.49) RAB9AMAPTSMN1; SMN2NPC1HPGD
SCHEMBL10050497 0.83 RAB9A (0.44) RAB9AMAPTSMN1; SMN2HSD17B10POLB
SCHEMBL10050511 0.81 TOP1 (0.54) RAB9AMAPTHSD17B10NPC1TOP1
SCHEMBL8908471 0.81 RAB9A (0.52) RAB9AMAPTSMN1; SMN2TDP1NPC1
SCHEMBL10050498 0.78 RAB9A (0.43) RAB9AMAPTSMN1; SMN2NPC1HPGD
SCHEMBL10050510 0.77 RAB9A (0.85) RAB9AMAPTSMN1; SMN2HSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8092661-B2 Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin BIOMERIEUX (FR) 2012-01-10 — — US disclosed
US-8092661-B2 Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin BIOMERIEUX (FR) 2012-01-10 — — US disclosed
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin BIOMERIEUX (FR) 2009-12-24 — — US disclosed
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin BIOMERIEUX (FR) 2009-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090314660-A1 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin EPS15, PPOX, ACR RAB9A 4754/4885MAPT 2894/4885SMN1; SMN2 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback